Cagrilintide 5mg Research Vial — Coming Soon to Peptify UK
Cagrilintide 5mg. Cagrilintide is an amylin receptor agonist peptide analogue being researched for its effects on appetite suppression, gastric emptying, and metabolic regulation in weight management studies. For research use only.
This research peptide is studied in published endocrine-signalling and metabolic-regulation research literature. Cagrilintide 5mg is supplied strictly as a lyophilised powder for in-vitro and preclinical research applications. Not approved by the MHRA for human therapeutic use; not for human consumption under any circumstances.
This 5mg vial is the entry-size research format — preferred for in-vitro pilot work, single-arm dose-finding, and short reconstitution windows. The smaller vial reduces lyophilised-stock waste between research cycles.
What ships with the Cagrilintide 5mg vial
- Lyophilised research peptide vial — Cagrilintide 5mg
- Janoshik Analytical Certificate of Analysis specific to the production lot (independent Czech laboratory, not in-house QC)
- HPLC purity report — 99%+ purity standard before any vial is released
- Mass-spectrometry identity confirmation on the same COA
- UK Royal Mail Tracked dispatch from London — same-day if ordered before 1pm
Why Cagrilintide 5mg is currently coming-soon, not in-stock
Every Peptify SKU is held back from sale until the Janoshik Analytical COA arrives for the specific production lot. This is a deliberate stock-control policy — no batch ships before its certificate is in our hands, no exceptions. The Cagrilintide 5mg batch is in the Janoshik test queue; this product page will flip from "Coming Soon" to "Add to basket" the moment the lot-specific COA lands.
Background literature on this compound is collected on the Peptify Cagrilintide research hub, which catalogues published preclinical findings, mechanism-of-action notes, and reference half-life data — all sourced and citation-anchored.
Stock alert sign-up
Enter your email on this page to be notified when Cagrilintide 5mg is released. Stock alerts go out the same hour the COA is uploaded — no marketing emails, no list-rental, just the one stock-back notification.
Supplier & compliance
PEPTIFY LIMITED is registered at Companies House under company number #17021295, incorporated 9 February 2026. Registered office: 6th Floor, 37 Lombard Street, London, EC3V 9BQ. UK IPO trademark applications under prosecution: UK00004350730 (word mark) and UK00004378672 (combined mark). All Peptify research peptides are sold for laboratory and preclinical research use only.
For research use only. Not for human consumption.